Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6088536 | 1.00 | MAOB (0.43) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL6091311 | 1.00 | MAOB (0.43) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL6092069 | 0.84 | POLB (0.42) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL6091547 | 0.84 | POLB (0.42) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL6089377 | 0.84 | POLB (0.42) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL6543372 | 0.80 | BACE1 (0.45) | RAB9ASMN1; SMN2ERN1LMNAL3MBTL1 | |
| SCHEMBL20139696 | 0.79 | MAOB (0.52) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL5783544 | 0.74 | MEN1 (0.52) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL5785350 | 0.74 | MEN1 (0.52) | MAOBMAOAMEN1KMT2ARAB9A | |
| SCHEMBL5786500 | 0.74 | MEN1 (0.52) | MAOBMAOAMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392292-B1 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-6998489-B2 | Methods of making indazoles | ALCON, INC. (CH) | 2006-02-14 | — | — | US | disclosed |
| US-6881749-B2 | Pyranoindazoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-19 | — | — | US | disclosed |
| EP-1513521-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2005-03-16 | — | — | EP | disclosed |
| EP-1392659-A4 | METHODS OF MAKING INDAZOLES | ALCON INC (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1392292-A4 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20040142998-A1 | Methods of making indazoles | ALCON, INC. (CH) | 2004-07-22 | — | — | US | disclosed |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | disclosed |
| EP-1392659-A1 | METHODS OF MAKING INDAZOLES | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1392292-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6696476-B2 | SUCH AS 1-(2-AMINOPROPYL)-1,7,8,9-TETRAHYDRO-PYRANO(2,3-G)-INDAZOL-8-OL; LOWERING AND CONTROLLING INTRAOCULAR PRESSURE | ALCON, INC. (CH) | 2004-02-24 | — | — | US | disclosed |
| WO-2003101379-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2003-12-11 | — | — | WO | disclosed |
| US-20030171418-A1 | Reducing or controlling eye pressure | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | disclosed |
| WO-2002098862-A1 | METHODS OF MAKING INDAZOLES | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098861-A1 | METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098350-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | PDE3A, CYP11B2, PDE3B | MAOB 454/4885MAOA 517/4885MEN1 2603/4885 |
| US-20030171418-A1 | Reducing or controlling eye pressure | PDE3A, PDE3B, QDPR | MAOB 244/4885MAOA 241/4885MEN1 2726/4885 |
| US-20040142998-A1 | Methods of making indazoles | NAT1, CYP3A5, ALDH3A1 | MAOB 57/4885MAOA 50/4885MEN1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.